Liberate Bio
Overview
Delivering genetic medicines that transcend liver-based limitations, liberating patients from disease.
Funding and backers
Team
11-50
employees, estimated range
Backers
1
Khosla Ventures
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 2023
Website went live first capture in the Wayback Machine
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
Protein Splicing to Develop the Next Generation of Genetic Medicines.
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Oisín Biotechnologies develops genetic medicines to address age-related diseases.
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
A bold visionfor genetic medicines AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Khosla VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely